PMC:3839092 / 5782-8268 JSONTXT

{"project":"2_test","denotations":[{"id":"24324445-23702452-41737764","span":{"begin":162,"end":163},"obj":"23702452"}],"text":"Participants\nThe sample population partially overlapped with that used for our previously published resting state functional magnetic resonance imaging research (8), and was comprised of 17 adolescents with MDD (ages 13–20 years, M = 16.8, SD = 2.2, 8 female) and 16 HC (ages 13–19 years, M = 16.4, SD = 1.4, 10 female) group matched for age, and all were right-handed. Depressed adolescents were recruited through the New York University (NYU) Child Study Center, the Bellevue Hospital Center Department of Psychiatry, and local advertisements in the NY metropolitan area. HC were recruited from the greater NY metropolitan area through local advertisements and from the families of NYU staff. The study was approved by the NYU School of Medicine and the Icahn School of Medicine at Mount Sinai institutional review boards. Prior to enrollment, study procedures were explained to the subjects and parents. Written informed consent was provided by participants age 18 and older; those under age 18 provided signed assent and a parent/guardian provided signed informed consent.\n\nInclusion and exclusion criteria\nAll subjects were ≤20 years old and did not present with any significant medical or neurological disorders. Other exclusionary criteria consisted of an IQ \u003c 80, MRI contraindications as assessed by a standard screening form, a positive urine toxicology test or a positive urine pregnancy test in females.\nAll MDD subjects met the DSM-IV-TR diagnosis of MDD with a current episode ≥8 weeks duration, and raw severity score ≥40 (i.e., T score ≥ 63) during the initial evaluation on the Children’s Depression Rating Scale-Revised (CDRS-R), and were psychotropic medication-free for at least 7 half-lives of the medication. To explore a wider range of depression severity we included patients presenting with mild to severe depression on the date of the scan. Exclusionary criteria for the MDD group included current or past DSM-IV-TR diagnoses of bipolar disorder, schizophrenia, pervasive developmental disorder, panic disorder, obsessive-compulsive disorder, conduct disorder, Tourette’s disorder, or a substance-related disorder in the past 12 months. Current diagnoses of post-traumatic stress disorder or an eating disorder were also exclusionary. In addition, acute suicidality requiring immediate inpatient admission was exclusionary. HC subjects did not meet the criteria for any major current or past DSM-IV-TR diagnoses and had never received psychotropic medication.\n"}

{"project":"NEUROSES","denotations":[{"id":"T196","span":{"begin":114,"end":124},"obj":"PATO_0001510"},{"id":"T197","span":{"begin":125,"end":133},"obj":"PATO_0001685"},{"id":"T198","span":{"begin":207,"end":210},"obj":"CHEBI_566274"},{"id":"T199","span":{"begin":1420,"end":1423},"obj":"CHEBI_566274"},{"id":"T200","span":{"begin":1464,"end":1467},"obj":"CHEBI_566274"},{"id":"T201","span":{"begin":1897,"end":1900},"obj":"CHEBI_566274"},{"id":"T202","span":{"begin":212,"end":216},"obj":"CHEBI_84123"},{"id":"T203","span":{"begin":271,"end":275},"obj":"CHEBI_84123"},{"id":"T204","span":{"begin":338,"end":341},"obj":"CHEBI_84123"},{"id":"T205","span":{"begin":961,"end":964},"obj":"CHEBI_84123"},{"id":"T206","span":{"begin":991,"end":994},"obj":"CHEBI_84123"},{"id":"T207","span":{"begin":252,"end":258},"obj":"PATO_0000383"},{"id":"T208","span":{"begin":312,"end":318},"obj":"PATO_0000383"},{"id":"T209","span":{"begin":320,"end":325},"obj":"CHEBI_24433"},{"id":"T210","span":{"begin":1901,"end":1906},"obj":"CHEBI_24433"},{"id":"T211","span":{"begin":338,"end":341},"obj":"PATO_0000011"},{"id":"T212","span":{"begin":961,"end":964},"obj":"PATO_0000011"},{"id":"T213","span":{"begin":991,"end":994},"obj":"PATO_0000011"},{"id":"T214","span":{"begin":356,"end":361},"obj":"PATO_0000367"},{"id":"T215","span":{"begin":568,"end":572},"obj":"PATO_0001323"},{"id":"T216","span":{"begin":625,"end":629},"obj":"PATO_0001323"},{"id":"T217","span":{"begin":739,"end":747},"obj":"CHEBI_23888"},{"id":"T218","span":{"begin":772,"end":780},"obj":"CHEBI_23888"},{"id":"T219","span":{"begin":1147,"end":1150},"obj":"CHEBI_52027"},{"id":"T220","span":{"begin":2362,"end":2365},"obj":"CHEBI_52027"},{"id":"T221","span":{"begin":1155,"end":1162},"obj":"PATO_0000467"},{"id":"T222","span":{"begin":1433,"end":1436},"obj":"CHEBI_16643"},{"id":"T223","span":{"begin":1433,"end":1436},"obj":"CHEBI_16811"},{"id":"T224","span":{"begin":1433,"end":1436},"obj":"CHEBI_16044"},{"id":"T225","span":{"begin":1441,"end":1444},"obj":"CHEBI_38624"},{"id":"T226","span":{"begin":1932,"end":1935},"obj":"CHEBI_38624"},{"id":"T227","span":{"begin":2418,"end":2421},"obj":"CHEBI_38624"},{"id":"T228","span":{"begin":1500,"end":1508},"obj":"PATO_0001309"},{"id":"T229","span":{"begin":1681,"end":1685},"obj":"PATO_0002316"},{"id":"T230","span":{"begin":2274,"end":2279},"obj":"PATO_0000389"},{"id":"T231","span":{"begin":1606,"end":1616},"obj":"PM3425"},{"id":"T232","span":{"begin":1759,"end":1769},"obj":"PM3425"},{"id":"T233","span":{"begin":1831,"end":1841},"obj":"PM3425"},{"id":"T234","span":{"begin":1824,"end":1841},"obj":"PM8322"},{"id":"T235","span":{"begin":1606,"end":1616},"obj":"PM3425"},{"id":"T236","span":{"begin":1759,"end":1769},"obj":"PM3425"},{"id":"T237","span":{"begin":1831,"end":1841},"obj":"PM3425"}],"text":"Participants\nThe sample population partially overlapped with that used for our previously published resting state functional magnetic resonance imaging research (8), and was comprised of 17 adolescents with MDD (ages 13–20 years, M = 16.8, SD = 2.2, 8 female) and 16 HC (ages 13–19 years, M = 16.4, SD = 1.4, 10 female) group matched for age, and all were right-handed. Depressed adolescents were recruited through the New York University (NYU) Child Study Center, the Bellevue Hospital Center Department of Psychiatry, and local advertisements in the NY metropolitan area. HC were recruited from the greater NY metropolitan area through local advertisements and from the families of NYU staff. The study was approved by the NYU School of Medicine and the Icahn School of Medicine at Mount Sinai institutional review boards. Prior to enrollment, study procedures were explained to the subjects and parents. Written informed consent was provided by participants age 18 and older; those under age 18 provided signed assent and a parent/guardian provided signed informed consent.\n\nInclusion and exclusion criteria\nAll subjects were ≤20 years old and did not present with any significant medical or neurological disorders. Other exclusionary criteria consisted of an IQ \u003c 80, MRI contraindications as assessed by a standard screening form, a positive urine toxicology test or a positive urine pregnancy test in females.\nAll MDD subjects met the DSM-IV-TR diagnosis of MDD with a current episode ≥8 weeks duration, and raw severity score ≥40 (i.e., T score ≥ 63) during the initial evaluation on the Children’s Depression Rating Scale-Revised (CDRS-R), and were psychotropic medication-free for at least 7 half-lives of the medication. To explore a wider range of depression severity we included patients presenting with mild to severe depression on the date of the scan. Exclusionary criteria for the MDD group included current or past DSM-IV-TR diagnoses of bipolar disorder, schizophrenia, pervasive developmental disorder, panic disorder, obsessive-compulsive disorder, conduct disorder, Tourette’s disorder, or a substance-related disorder in the past 12 months. Current diagnoses of post-traumatic stress disorder or an eating disorder were also exclusionary. In addition, acute suicidality requiring immediate inpatient admission was exclusionary. HC subjects did not meet the criteria for any major current or past DSM-IV-TR diagnoses and had never received psychotropic medication.\n"}